The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 24799086 |
74 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump. |
Pfizer Inc |
| 20829430 |
218 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. |
Amgen Inc |
| 27031670 |
16 |
Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery. |
Astex Pharmaceuticals |
| 26502061 |
6 |
Targeting Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MAPKAPK2, MK2): Medicinal Chemistry Efforts To Lead Small Molecule Inhibitors to Clinical Trials. |
Universit£ di Siena |
| 21965623 |
170 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. |
AstraZeneca |
| 25310383 |
50 |
Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition. |
Novartis Institutes for BioMedical Research |
| 24900633 |
11 |
Structure-based design of 2-aminopyridine oxazolidinones as potent and selective tankyrase inhibitors. |
Amgen Inc |
| 12739759 |
25 |
Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. |
Schering-Plough Research Institute |
| 12404239 |
6 |
The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. |
King's College Hospital |
| 30034601 |
70 |
Structure-Activity Relationship of Novel and Selective Biaryl-Chroman GPR40 AgoPAMs. |
Merck & Co. |
| 23956101 |
2441 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
Amgen Inc |
| 22961681 |
621 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. |
AstraZeneca |
Search and Browse
